research Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
Search
for
Sort by
Research
150-180 / 1000+ results research Treatment of Alopecia Areata with Simvastatin/Ezetimibe
Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.
research How to manage an 18-20 year old with hair loss that is not improved with ketoconazole?
Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
research How to manage an 18-20 year old with hair loss that is not improved with ketoconazole?
Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.
research Acute Moist Dermatitis with Thrombocytopenia in Cat
A young Persian cat had a skin infection and low platelets, treated with various medications.
research Efficacy of antihistamines in combination with topical corticosteroid and superficial cryotherapy for treatment of alopecia areata: A retrospective cohort study
Adding antihistamines to topical corticosteroid and cryotherapy may improve hair regrowth in alopecia areata patients.
research Effect of Long-Term Fluticasone Treatment on Immune Function in Horses with Heaves
Long-term fluticasone treatment does not harm the immune system in horses with heaves.
research Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising
Social media can help compare the effectiveness and safety of new arthritis medications.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research 24 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
research Fármacos de uso frecuente en dermatología como terapia para COVID-19
Common dermatology drugs were considered but are controversial for COVID-19 treatment.
research Biology, diagnosis and treatment of Malassezia dermatitis in dogs and cats
The conclusion is that certain dog and cat breeds are prone to Malassezia dermatitis, which can be diagnosed with skin tests and treated with antifungal shampoos or medications, and preventing relapses involves managing underlying issues and maintaining good hygiene.
research Decision letter: Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis
Neutrophils are key in causing chronic itch in atopic dermatitis, and blocking CXCR3 could reduce this itch.
research Antidiabetic, dermatoprotective, antioxidant and chemical functionalities in Zizyphus lotus leaves and fruits
Zizyphus lotus leaves and fruits have strong antidiabetic effects and potential skin benefits.
research Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-κB inhibition
A new cream, DHMEQ, reduces allergic skin inflammation effectively.
research Arthritis drug spurs hair regrowth in alopecia patient
An arthritis drug helped a person with severe hair loss regrow their hair.
research Scabiosis, Otitis Externa, With Toxocariosis and Ancylostomiasis In Local Cat
The cat's health improved significantly after treatment.
research Preparation and Physicochemical Evaluation of Topical Cream Ivermectin 1% for Treatment of Rosacea
A stable ivermectin cream may effectively treat rosacea without long-term antibiotics.
research Case of intractable ophiasis type of alopecia areata presumably improved by fexofenadine
Fexofenadine may help treat a difficult type of hair loss.
research DERMATOPHYTOSIS CAUSED BY TRICHOPHYTON SPP. IN A LOCAL KITTEN
The kitten's skin condition improved significantly after 4 weeks of treatment.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Dermatologic Diseases
The document concludes that early diagnosis and treatment are crucial for managing skin diseases in ferrets.
research Evolution, mechanism of action, and clinical applications of three generations of antihistamines
Third-generation antihistamines are the safest and most effective for allergies.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Review of Promising Off-Label Use of Deucravacitinib
Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Drug Information Analysis Service
Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
research The effectiveness of acaricidal drugs in bovine psoroptosis
Deltsid 7.5 is the most effective treatment for bovine psoroptosis.
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.